A careful calibration: balancing small molecule needs and biologic innovation
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
List view / Grid view
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
The $11bn collaboration with the Chinese biopharma company gives Takeda the rights to several next-generation candidates.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.